

Nafithromycin: advancements in antibiotic therapy against community-acquired pneumonia-resistant pathogens

Akshata Gore, Agadi Hiremath Viswanatha Swamy, Sanatkumar Bharamu Nyamagoud

Department of Pharmacy Practice, KLE College of Pharmacy, Vidyanagar, Hubballi, Karnataka, India

Abstract

Nafithromycin (WCK 4873) is a novel lactone ketolide antibiotic developed to address the critical issue of multidrug-resistant bacteria, especially those causing community-acquired pneumonia (CAP). Given the increasing prevalence of antibiotic resistance, there is a pressing need for new antibiotics with improved efficacy and safety profiles. This review synthesizes data from various *in vitro* studies and clinical trials to evaluate the pharmacological properties, mechanism of action, and clinical potential of nafithromycin. Key clinical trials assessed the drug's pharmacokinetics, safety, and efficacy in both healthy volunteers and patients with CAP.

Nafithromycin exhibits strong *in vitro* antimicrobial activity against a broad spectrum of pathogens, including macrolide-resistant and telithromycin-insensitive strains. Clinical trials demonstrated that nafithromycin has a favorable pharmacokinetic profile, with high lung tissue concentrations and manageable side effects. Phase I studies confirmed its safety and tolerability in healthy adults, while Phase II trials showed its efficacy in treating CAP, with a 3-day treatment regimen proving comparable to a 7-day regimen of moxifloxacin.

Nafithromycin holds significant promise as a therapeutic agent against respiratory infections caused by resistant bacteria. Its unique mechanism of action, high tissue penetration, and broad-spectrum activity position it as a valuable addition to the antimicrobial arsenal. Continued research and clinical trials are essential to further define its role in combating antibiotic resistance and ensuring effective treatment options.

Key words: nafithromycin, community-acquired pneumonia, multidrug-resistant bacteria, lactone ketolide antibiotic, pharmacokinetics.

Correspondence to: Sanatkumar Bharamu Nyamagoud, Department of Pharmacy Practice, KLE College of Pharmacy, Vidyanagar, Hubballi, India. Tel.: +917795641008. E-mail: dr.sanathnyamagoud@gmail.com

Introduction

Nafithromycin, also identified as WCK 4873, is a novel lactone ketolide antibiotic developed to combat multidrug-resistant bacteria, particularly those causing community-acquired pneumonia (CAP). Its unique chemical structure and mechanism of action make it a promising candidate in the ongoing fight against antibiotic-resistant infections [1].

The rise in antibiotic resistance underscores an urgent need for novel therapeutic agents. Nafithromycin, a macrolide antibiotic, stands out due to its unique structural adaptations, which enhance its pharmacokinetics and antimicrobial effectiveness compared to traditional macrolides like azithromycin [2]. This review delves into its pharmacological features, mechanism of action, and clinical potential. As a macrolide, it shows promise in treating various bacterial infections, including respiratory and skin infections. Its unique structural features and comparative effectiveness against existing antibiotics highlight its therapeutic potential [3].

As a macrolide antibiotic, nafithromycin exhibits significant potential in treating bacterial infections, particularly respiratory and skin infections. It demonstrates robust *in vitro* activity against a

wide range of pathogens, including both typical and atypical bacteria implicated in community-acquired lower respiratory tract infections. Its efficacy has been noted against *Streptococcus pneumoniae*, with minimum inhibitory concentration 90 (MIC₉₀) values of 0.06 mg/L and activity against macrolide-resistant strains. Other susceptible bacteria include *Moraxella catarrhalis*, *Haemophilus influenzae*, *Staphylococcus aureus*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella pneumophila* [4].

Class: antibacterials; hexoses; ketolides; lactones; macrolides; pyridines; thiadiazols.

Background on antibiotic resistance

The widespread misuse and overuse of antibiotics have exacerbated the issue of resistance. Pathogens such as methicillin-resistant *Staphylococcus aureus* and macrolide-resistant *Streptococcus pneumoniae* have highlighted the need for next-generation antibiotics. The Centers for Disease Control and Prevention has recognized antimicrobial resistance as a severe public health threat, reinforcing the importance of developing agents like nafithromycin to address these challenges [1,5].



Synthesis and chemical properties

The synthesis of nafithromycin involves advanced chiral strategies to ensure high purity and yield. Bhavsar *et al.* (2023) detailed the development of efficient synthetic routes for nafithromycin, focusing on the production of the antibiotic with precise chiral properties essential for its biological activity. This research highlights the novel chemical pathways and optimization techniques used to enhance the synthesis process. Its chemical structure (C₄₂H₆₂N₆O₁₁S) is shown in Figure 1, characterized by a lactone ring and specialized substituents, contributing to its enhanced stability, bioavailability, and resistance to bacterial degradation [6]. These structural innovations support its robust antimicrobial activity and therapeutic potential.

Mechanism of action

Nafithromycin exerts its antibacterial effects by obstructing bacterial protein synthesis. It binds to the 50S ribosomal subunit, preventing the elongation of the peptide chain and thereby disrupting protein synthesis. This mechanism is similar to that of other macrolides but with structural modifications that enhance its activity against resistant bacterial strains. Krokidis *et al.* (2013) provided insights into the binding interactions of nafithromycin with the ribosomal subunit, explaining its effectiveness in inhibiting protein synthesis [2,7].

The structural modifications in nafithromycin, particularly the lactone ring, enhance its ability to overcome common resistance mechanisms employed by bacteria, such as efflux pumps and ribosomal protection proteins. This makes nafithromycin active against strains that have developed resistance to other macrolides and ketolides. Its ability to inhibit protein synthesis at multiple sites on the ribosome further reduces the likelihood of resistance development [8].

Clinical trials of nafithromycin: phases of clinical trials

Table 1 shows the phases of clinical trials of nafithromycin [9-14].

Nafithromycin, a new lactone ketolide, is being developed for its potential in treating bacterial infections, especially due to its high and lasting concentrations in the lungs. This unique property allows it to effectively combat macrolide-resistant strains of *Streptococcus pneumoniae* with a shorter, 3-day treatment course. Phase I studies in China and ongoing Phase 3 trials in India confirm that nafithromycin achieves significantly higher concentrations in lung tissues compared to plasma, enhancing its ability to kill intracellular bacteria and ensure effective delivery to infection sites [15]. In Phase II trials, nafithromycin demonstrated comparable effectiveness to a 7-day regimen of moxifloxacin for treating community-acquired bacterial pneumonia, supporting its use in a 3-day, once-daily dosing schedule. Its distinct chemical structure contributes to its efficacy and extended lung exposure. Additionally, nafithromycin has shown promise in reducing inflammation in acute lung injury models, further supporting its therapeutic potential. Its MIC₉₀ of 0.06 mg/L indicates strong activity against resistant strains, aligning with its global efficacy [16].

In vitro activity

Nafithromycin has been shown in numerous studies to have strong *in vitro* activity against a variety of bacterial pathogens. According to Flamm *et al.* (2017), it has broad-spectrum activity against modern clinical bacteria, including antibiotic-resistant ones, that were gathered from a global surveillance program. In particular, its effectiveness against *Chlamydia pneumoniae*, a significant pathogen in respiratory infections, was emphasized by Kohlhoff and Hammerschlag (2021) [8,16,17].

The potential of nafithromycin to treat infections brought on by resistant bacteria is highlighted by these *in vitro* investigations. It is a versatile antibiotic due to its efficacy against a broad range of pathogens, such as *Staphylococcus aureus*, *Haemophilus influenzae*, and *Streptococcus pneumoniae*. Nafithromycin has the potential to overcome current resistance mechanisms, as evidenced by Zhou *et al.*'s (2022) demonstration of its activity against isolates of *Streptococcus pneumoniae* that are resistant to macrolides [18].

Safety and tolerability

The safety and tolerability of nafithromycin have been evaluated in various clinical trials. Iwanowski *et al.* (2019) reported that nafithromycin is well-tolerated in healthy adult subjects, with minimal adverse effects. Common side effects were mild and included gastrointestinal disturbances, which are typical of macrolide antibiotics [19].

The favorable safety profile of nafithromycin is attributed to its selective targeting of bacterial ribosomes, which reduces the likelihood of off-target effects on human cells. This selectivity is a significant advantage, as it minimizes the risk of adverse reactions and makes nafithromycin suitable for use in a broad range of patients, including those with comorbid conditions [18,19].

Pharmacokinetics

The pharmacokinetic profile of nafithromycin is characterized by good oral bioavailability, effective plasma concentrations, and favorable distribution in tissues. Iwanowski *et al.* (2019) conducted studies to assess its safety, tolerability, and pharmacokinetics, revealing that nafithromycin is well-tolerated in healthy adults with or without food, and maintains therapeutic concentrations over an extended period [19].




Figure 1. Structure of nafithromycin: C₄₂H₆₂N₆O₁₁S. Modified from: National Center for Biotechnology Information, 2025 [5].



Table 1. Phases of clinical trials of nafithromycin.

Trial no.	Phase CTID	Study title	Design	Population	Intervention	Explanation	Time frame
1	Phase INCT02453529	A Phase I, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects	Multiple-dose, open-label study	36 healthy adults (18-55 years)	WCK 4873 (oral, 3 doses daily)	Plasma and intrapulmonary concentrations of nafithromycin were assessed; 37 AEs (mostly mild, e.g., headaches, dysgeusia). Study confirmed favorable PK and tolerability [9].	April-July 2015
2	Phase INCT02770404	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Single-Ascending Doses of Intravenous Nafithromycin in Healthy Adult Subjects	Double-blind, randomized, placebo-controlled study	60 healthy adults (18-55 years)	IV nafithromycin (100-400 mg) or a placebo with an 8:2 randomization ratio	Safety and PK parameters (AUC, Cmax) were evaluated across ascending doses. Mild AEs confirmed tolerability [10].	April-December 2016
3	Phase INCT03926962	Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Ascending Doses And The Effect Of Food On Oral WCK 4873 In Healthy Adult Volunteers		67 healthy adults (18-65 years)	Oral WCK 4873 (100-1200 mg)	Food impact study showed consistent PK outcomes with no significant safety concerns across doses. Established suitability for oral administration [11].	March-July 2013
4	Phase INCT03979859	Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Oral Doses Of WCK 4873 In Healthy Adult Volunteers	Randomized, double-blind, single-center, placebo-controlled, sequential cohort study	30 participants (18-55 years)	Ascending doses of WCK 4873 or placebo once daily under fed conditions for 7 days	Evaluated ascending doses under fed conditions. PK data (e.g., AUC, Tmax) confirmed safety and sustained drug absorption [12].	August-December 2013
5	Phase INCT03981887	A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Intravenous Nafithromycin in Healthy Subjects	Randomized, double-blind, placebo-controlled study	10 healthy adults (18-55 years)	IV nafithromycin (200 mg BID)	Multiple-dose regimen confirmed favorable PK (high AUC, long half-life) and manageable AEs. Study supported effective systemic delivery via IV route [13].	June-August 2019
6	Phase INCT02903836	A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in adults	Randomized, double-blind study	231 CABP patients (adults)	Oral nafithromycin (800 mg every 24 hours for 3 days) to oral moxifloxacin (400 mg every 24 hours for 7 days)	Clinical efficacy comparable to moxifloxacin (7 days) for CABP treatment. Shorter 3-day regimen was effective for symptom resolution, supporting nafithromycin's therapeutic potential [14].	November 2016- July 2017

CTID, clinical trial identifier; WCK 4873, nafithromycin; IV, intravenous; BID, bis in die; AEs, adverse events; PK, pharmacokinetics; AUC, area under the curve; Tmax, time to maximum concentration.



Nafithromycin's pharmacokinetics are optimized for treating respiratory infections. Its high tissue penetration, particularly in lung tissues, ensures that effective drug concentrations are achieved at the site of infection. This is crucial for treating pneumonia and other respiratory tract infections. Additionally, its pharmacokinetic properties allow for convenient dosing regimens, which can enhance patient adherence and treatment outcomes [20].

Clinical implications and usage

Nafithromycin has shown significant promise in clinical settings, particularly in the treatment of CAP. Sellarès-Nadal *et al.* (2020) reviewed investigational drugs for CAP and emphasized the potential role of nafithromycin due to its robust activity against key pathogens and its favorable pharmacokinetic profile [21]. Clinical trials and real-world studies support its use in diverse patient populations, highlighting its efficacy and safety [22].

The Infectious Diseases Society of America and the American Thoracic Society have developed guidelines for the management of CAP, which include recommendations for the use of new antibiotics like nafithromycin. These guidelines highlight the need for antibiotics that can effectively treat resistant pathogens and improve patient outcomes. Nafithromycin's broad-spectrum activity and favorable safety profile make it a valuable option for clinicians managing CAP [23].

Resistance mechanisms and overcoming challenges

New antibiotics like nafithromycin must be developed in order to address the growing problem of antibiotic resistance. Solomon and Oliver (2014) discussed the critical threat posed by antibiotic resistance in the United States and the importance of new antibiotics to address this challenge. Nafithromycin is effective against strains resistant to other antibiotics because it has been demonstrated to circumvent common resistance mechanisms like ribosomal protection proteins and efflux pumps [24].

Khande *et al.* (2017) studied the impact of hyper *ermB* induction in *Streptococcus pneumoniae* and *Staphylococcus aureus* on the activity of nafithromycin, demonstrating its ability to maintain activity against these resistant strains [25]. This highlights the potential of nafithromycin to be used as a frontline treatment for infections caused by multidrug-resistant bacteria.

Comparative studies

Comparative studies have demonstrated the superiority of nafithromycin over existing antibiotics in certain clinical scenarios. Garin *et al.* (2014) examined the potential advantages of incorporating a macrolide or ketolide, such as nafithromycin, to improve treatment efficacy in moderately severe CAP by contrasting β -lactam monotherapy with β -lactam-macrolide combination treatment.

These comparative studies are essential for establishing nafithromycin's place in clinical practice. By demonstrating its advantages over current treatment options, nafithromycin can be positioned as a preferred choice for treating CAP and other respiratory infections, particularly in settings where resistance to traditional antibiotics is prevalent [26].

Future directions and research

Continued research is essential to fully understand the potential of nafithromycin and its role in treating antibiotic-resistant infections. Future studies should focus on its long-term safety, potential for resistance development, and effectiveness in diverse patient populations. Additionally, exploring its use in combination therapies could further enhance its efficacy and expand its clinical applications [27].

Research should also investigate the potential of nafithromycin to treat other types of infections beyond respiratory tract infections. Given its broad-spectrum activity, it may be useful in treating a range of bacterial infections, such as those of the skin, soft tissues, and perhaps even the gastrointestinal tract [28].

Conclusions

Nafithromycin represents a significant advancement in antibiotic therapy, especially for treating respiratory infections caused by resistant bacteria. It is a promising candidate for clinical use due to its distinct mechanism of action, advantageous pharmacokinetic characteristics, and broad-spectrum activity. Continued research and clinical trials will further define its role in the antimicrobial arsenal and its impact on public health.

The development of nafithromycin underscores the importance of innovation in the field of antibiotic research. As antibiotic resistance continues to pose a significant threat, new antibiotics like nafithromycin are crucial for maintaining effective treatment options and safeguarding public health.

References

- Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2019;44:S27-72.
- Bhawsar S, Ravikumar T, Sunil G, et al. Design and development of efficient synthetic strategies for the chiral synthesis of novel ketolide antibiotic, nafithromycin (WCK 4873). *Chemical Papers* 2023;77:3629-40.
- Chavan R, Zope V, Chavan N, et al. Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic. *Xenobiotica* 2021;51:251-61.
- Patil KR, Yeole RD, Zwart M, Pruijm P. Simultaneous determination of novel ketolide antibiotic nafithromycin and its major metabolite in human plasma using liquid chromatography tandem mass spectrometry. *Bioanalysis* 2019;11:1767-76.
- National Center for Biotechnology Information. PubChem compound summary for CID 117587595, nafithromycin. 2025. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Nafithromycin>.
- Krokidis MG, Márquez V, Wilson DN, et al. Insights into the mode of action of novel fluoroketolides, potent inhibitors of bacterial protein synthesis. *Antimicrob Agents Chemother* 2013;58:472-80.
- Garin N, Genné D, Carballo S, et al. β -lactam monotherapy vs β -lactam-macrolide combination treatment in moderately severe community-acquired pneumonia. *JAMA Intern Med* 2014;174:1894-901.
- Flamm RK, Rhomberg PR, Sader HS. In vitro activity of the



- novel lactone ketolide nafithromycin (WCK 4873) against contemporary clinical bacteria from a global surveillance program. *Clin Microbiol Infect* 2017;61:e01230-17.
9. U.S. National Library of Medicine. Available from: <https://clinicaltrials.gov/>.
 10. A phase I pharmacokinetic study of single-ascending doses of intravenous nafithromycin in healthy adult subjects. Available from: <https://trial.medpath.com/clinical-trial/0f9f39a62bbd0dfb/nct02770404-safety-tolerability-pharmacokinetic-study-nafithromycin>.
 11. The safety, tolerability and pharmacokinetics of single ascending doses and the effect of food on oral WCK 4873 in healthy adult volunteers. Available from: <https://trial.medpath.com/clinical-trial/535bb7d742c42765/double-blind-randomized-placebo-controlled-study-wck-4873>.
 12. Evaluate the safety, tolerability and pharmacokinetics of multiple ascending oral doses of WCK 4873 in healthy adult volunteers. Available from: <https://trial.medpath.com/clinical-trial/3a58bf3c46f6e4d5/double-blind-randomized-placebo-controlled-study-wck-4873>.
 13. Safety, tolerability, and pharmacokinetics of multiple doses of intravenous nafithromycin. Available from: <https://trial.medpath.com/clinical-trial/1b0a74c0753f2ce4/safety-tolerability-pharmacokinetics-nafithromycin>.
 14. Phase II study of oral nafithromycin in CABP. Available from: <https://trial.medpath.com/clinical-trial/70788141238f88d4/oral-nafithromycin-moxifloxacin-cabp-treatment>.
 15. Veeraraghavan B, Varghese R, Saigal K, et al. Activity of novel lactone ketolide nafithromycin against multicentric invasive and non-invasive pneumococcal isolates collected in India. *JAC Antimicrob Resist* 2021;3:dlab066.
 16. Bhavnani SM, Trang M, Griffith DC, et al. Pharmacokinetic-pharmacodynamic target attainment analyses as support for meropenem-vaborbactam dosing regimens and susceptibility breakpoints. *Antimicrob Agents Chemother* 2022;66:e0213021.
 17. Kohlhoff S, Hammerschlag MR. In vitro activity of nafithromycin (WCK 4873) against *Chlamydia pneumoniae*. *Antimicrob Agents Chemother* 2021;65:e0058521.
 18. Zhou M, Wu L, Kang W, et al. In vitro activity of lactone ketolide nafithromycin (WCK 4873) against *Streptococcus pneumoniae* isolates enriched with macrolide-resistance phenotype collected from mainland China. *J Clin Microbiol* 2022;4:dlacl103.
 19. Iwanowski P, Bhatia A, Gupta M, et al. Safety, tolerability, and pharmacokinetics of oral nafithromycin (WCK 4873) after single or multiple doses and effects of food on single-dose bioavailability in healthy adult subjects. *Antimicrob Agents Chemother* 2019;63:e01253-19.
 20. Rodvold KA, Gotfried MH, Chugh R, et al. Plasma and intrapulmonary concentrations of cefepime and zidebactam following intravenous administration of WCK 5222 to healthy adult subjects. *Antimicrob Agents Chemother* 2018;62:e00682-18.
 21. Sellarès-Nadal J, Burgos J, Falcó V, Almirante B. Investigational and experimental drugs for community-acquired pneumonia: the current evidence. *J Exp Pharmacol* 2020;12:529-38.
 22. CDC. 2019 antibiotic resistance threats report. 2024. Available from: <https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html>.
 23. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med* 2019;200:e45-67.
 24. Solomon SL, Oliver KB. Antibiotic resistance threats in the United States: stepping back from the brink. *Am Fam Physician* 2014;89:938-41.
 25. Khande H, Satav J, Kulkarni A, et al. WCK 4873 (nafithromycin): impact of hyper ermB induction in *S. pneumoniae* and *S. aureus* on the activity of ketolides. European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 2017. Abstract P-1350.
 26. Trivedi J, Shaikh J, Chavan N, et al. Pretreatment of nafithromycin attenuates inflammatory response in murine lipopolysaccharide induced acute lung injury. *Cytokine* 2020;129:155049.
 27. Veeraraghavan B, Varghese R, Saigal K, et al. Activity of novel lactone ketolide nafithromycin against multicentric invasive and non-invasive pneumococcal isolates collected in India. *JAC Antimicrob Resist* 2021;3:dlab066.
 28. Hackel M, Karlowsky JA, Dressel DC, Sahm DF. Determination of disk diffusion and MIC quality control ranges for nafithromycin (WCK 4873), a new lactone-ketolide. *J Clin Microbiol* 2017;55:3021-7.

Received: 7 January 2025; Accepted: 5 March 2025; Early view: 5 August 2025.

Contributions: All authors have contributed significantly. Akshata Gore: conceptualized the review, formulated the scope, conducted an extensive literature search, organized the retrieved data and designed the structure of the manuscript. Agadi Hiremath Viswanatha Swamy, Sanatkumar Bharamu Nyamagoud: critically reviewed and refined the content, ensuring accuracy and coherence throughout the manuscript. All authors actively contributed to discussions, approved the final version, and agree to be accountable for all aspects of the work.

Conflict of interest: the authors declare no potential conflicts of interest.

Ethics approval and consent to participate: not applicable. This study is a review of existing literature and does not involve human participants or animals requiring ethical approval or consent to participate.

Informed consent: not applicable.

Patient consent for publication: not applicable.

Availability of data and materials: this manuscript is a review article based on previously published research and publicly available datasets. All data supporting the findings are derived from publicly accessible sources, which are appropriately cited in the manuscript. No new datasets were generated during the study.

Acknowledgments: the authors express their sincere gratitude to the Vice-Chancellor, Registrar, and Dean of Pharmacy, KLE Academy of Higher Education and Research, Belagavi, for their invaluable support and encouragement.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

